ARK Invest's position in CGEN, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| IZRL | 951,502 | $2.0M | 1.63% | #22 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-15 | IZRL | Buy | Added | 73,260 | $158K |
| 2026-10-14 | IZRL | Buy | Added | 15,930 | $32K |
| 2026-07-16 | IZRL | Buy | Added | 65,117 | $154K |
| 2026-07-15 | IZRL | Buy | Added | 45,740 | $108K |
| 2026-04-27 | IZRL | Sell | Trimmed | 91,354 | $277K |
| 2026-04-24 | IZRL | Sell | Trimmed | 30,953 | $89K |
| 2026-04-23 | IZRL | Sell | Trimmed | 18,342 | $51K |
| 2026-04-20 | IZRL | Sell | Trimmed | 5,879 | $17K |
| 2026-04-17 | IZRL | Sell | Trimmed | 16,834 | $49K |
| 2026-04-16 | IZRL | Sell | Trimmed | 83,422 | $233K |
| 2026-04-15 | IZRL | Sell | Trimmed | 16,553 | $48K |
| 2026-01-15 | IZRL | Buy | Added | 979,811 | $2.1M |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been…
See CGEN's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open CGEN on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.